Outsourcing Pharma

JUNE 3, 2021

COVID-19 vaccination via Vaxxasâ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.

Vaccines 96

Vaccines 96

Pharmacy Times

MAY 1, 2023

Analysis shows that the ratio of neutralizing antibody geometric mean titers in adolescents compared with young adults was 1.5 after vaccination with NVX-CoV2373.

Vaccines 153

Vaccines 153

Drug Topics

MARCH 27, 2024

mRNA-1283 generated a stronger immune response against both the Omicron BA.4/BA.5 5 and the original virus strains of SARS-CoV-2 compared with Spikevax, Moderna’s licensed COVID-19 vaccine.

Vaccines 163

Vaccines Immunization 163

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Immunization 107

Immunization Vaccines Hospitals 107

Drug Topics

NOVEMBER 7, 2023

The FDA is advising health care professionals who administer the vaccine to make sure the correct volume of the vaccine is withdrawn from the vial and the correct dose is administered to the patient.

Vaccines 98

Vaccines FDA 98

Pharmacy Times

JUNE 28, 2023

During the pandemic, many community pharmacists also gained the authority to provide routine vaccinations for child populations.

Community Pharmacies 123

Community Pharmacies Vaccines 123

Drug Topics

JANUARY 4, 2024

In response to a surge in cases of COVID-19, flu, and RSV, hospitals are reinstating mask guidelines to avoid adverse capacity outcomes and staffing shortages seen in prior years.

Hospitals 201

Hospitals 201

Drug Topics

OCTOBER 21, 2022

Moderna’s bivalent mRNA COVID-19 booster reached prespecified superiority and noninferiority criteria against multiple strains of SARS-CoV-2.

144

144

STAT

FEBRUARY 2, 2023

China’s massive Covid-19 crisis, sparked in part by the country’s rolling back its strict zero-Covid policies in early December, has seen millions of people infected with SARS-CoV-2.

100

100

Pharmacy Times

SEPTEMBER 14, 2023

Compared with COVID-19 vaccination alone, recent study findings show health care workers who received both a COVID-19 booster and influenza vaccinations did not have lower immune response or more frequent adverse events.

Vaccines 139

Vaccines Immunization 139

Drug Topics

FEBRUARY 22, 2023

public health emergency response to COVID-19 ends on May 11. More traditional health care coverage will begin when the U.S.

Vaccines 187

Vaccines 187

STAT

APRIL 26, 2024

Their shared mission is to continue to improve the care they provide their patients; their shared responsibility is to do so without increasing costs by shifting from fee-for-service to value-based care.

Hospitals 126

Hospitals 126

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. Moderna acknowledged that this patient population has the greatest risk for severe outcomes from COVID-19. Moderna’s Spikevax XBB.1.5-adapted

Vaccines 87

Vaccines Immunization 87

Pharmacy Times

JUNE 28, 2022

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

123

123

Pharmacy Times

OCTOBER 27, 2022

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

Vaccines 122

Vaccines 122

Outsourcing Pharma

JANUARY 28, 2021

As the COVID-19 vaccines continue the early stages of circulation in the US, the agency keeps an eye on industry actions and offers advice to key players.

FDA 87

FDA Vaccines 87

Pharma Times

JULY 18, 2021

Studies showed immunosuppression appeared to weaken immune responses to COVID-19 vaccines

Vaccines 49

Vaccines Immunization 49

STAT

JANUARY 18, 2024

Long Covid has long eluded scientists looking for its cause. New research published Thursday in Science has identified proteins present in the blood of people with long Covid that could point the way to a much-needed diagnostic test and possibly to future therapeutic targets.

Immunization 145

Immunization 145

Outsourcing Pharma

OCTOBER 20, 2020

A leader from a New Zealand-based CRO talks about the countryâs handling of the pandemic, and how their low rates are making sponsors take notice.

95

95

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). MHRA authorisation of Bimervax The COVID-19 vaccine, developed by HIPRA Human Health, combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, according to the MHRA.

Vaccines 96

Vaccines Immunization 96

Fierce Healthcare

AUGUST 17, 2023

As one of a small group of people working to develop and deploy COVID-19 testing at the very start of the pandemic, I witnessed both major blunders and genius breakthroughs, but what sticks with me | There are lessons we learned during the COVID-19 response that can and should inform our response to today’s record levels of depression, anxiety and (..)

98

98

Outsourcing Pharma

OCTOBER 5, 2020

As the pandemic maintains its hold, the US agency continues to issue advice and take action related to testing, treatment and information on the virus.

FDA 52

FDA 52

European Pharmaceutical Review

MARCH 9, 2023

A pilot study has demonstrated that a nasal version of the drug Foralumab, an anti-CD3 monoclonal antibody suppressed the inflammatory T cell response and decreased lung inflammation in patients with COVID-19. The paper was published in Proceedings of the National Academy of Sciences.

Immunization 145

Immunization Medical Schools Hospitals Vaccines 145

Pharmacy Times

SEPTEMBER 8, 2022

Children younger than age 6 years might be protected from other COVID-19 variants for up to a year after infection.

Immunization 123

Immunization 123

Fierce Pharma

OCTOBER 4, 2023

government is winding down its distribution of COVID-19 countermeasures. | The government will wind down its Lagevrio distribution ahead of the transition, the Administration for Strategic Preparedness and Response said. As long expected, the U.S.

112

112

Pharmaceutical Technology

JUNE 20, 2023

The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.

Vaccines 145

Vaccines Pharmaceutical Companies Pharmaceutical Companies 145

European Pharmaceutical Review

NOVEMBER 1, 2023

adapted COVID-19 vaccine, developed by Novavax for this autumn and winter season. is to be used for preventing COVID-19 in adults and children from 12 years of age. 5, it was able to trigger a strong immune response against this strain. is expected to trigger an adequate immune response against XBB.1.5.

Vaccines 94

Vaccines Immunization 94

Hospital Pharmacy Europe

SEPTEMBER 25, 2023

The General Pharmaceutical Council (GPhC) has received instruction by the UK Government to close its temporary Covid-19 register in March 2024. The temporary register was set up in 2020 when the GPhC used its emergency powers to register pharmacy professionals rapidly in response to the Covid-19 pandemic.

Hospitals 105

Hospitals 105

STAT

SEPTEMBER 27, 2022

Gavin Newsom that strengthens discipline for doctors who knowingly spread Covid-19 misinformation. More than two years into the pandemic, Covid-19 misinformation still runs rampant. Physicians account for three of the 12 individuals thought to be responsible for up to 73% of anti-vaccine content on Facebook.

Vaccines 145

Vaccines Immunization 145

Fierce Pharma

SEPTEMBER 13, 2023

Moderna has spent the last several years riding the ups and downs of the COVID-19 pandemic. Moderna CEO Stéphane Bancel is optimistic that the company will beat the low end of its $6 billion to $8 billion COVID vaccine sales estimate for 2023.

Vaccines 104

Vaccines 104

STAT

MAY 10, 2023

On the eve of the expiration date for the federally declared coronavirus public health emergency , White House Covid-19 Response Coordinator Ashish Jha warned that the pandemic is far from over. “I don’t see this as an end to the pandemic or fighting Covid,” Jha said at a STAT event in Boston on Wednesday.

134

134

STAT

APRIL 29, 2024

The steady increase was largely attributed to the initial response among many companies to quickly develop salves for the Covid-19 pandemic. Continue to STAT+ to read the full story…

111

111

Pharmacy Times

OCTOBER 18, 2022

5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech) increases neutralizing antibody response against multiple variants of Omicron. Research showed the Omicron BA.4/BA.5-adapted

Vaccines 165

Vaccines 165

Fierce Pharma

AUGUST 18, 2023

Thursday, Moderna presented preliminary data from a clinical trial of its updated mRNA shot, showing that it generates a robust response against currently circulating variants.

Vaccines 94

Vaccines 94

STAT

JULY 31, 2023

When the Covid-19 pandemic began in 2020, some experts assumed the virus would affect everyone even-handedly, regardless of their race or socioeconomic background. But the reality of Covid proved to be far from the “great equalizer” — Black and brown communities had higher rates of infection and death.

98

98

Outsourcing Pharma

DECEMBER 22, 2020

The GoGetTested response operating system, to date used to administer more than 200,000 tests, now will scale to include health systems in more states.

52

52

STAT

APRIL 24, 2023

response to the Covid-19 pandemic paints a picture of a country ill-prepared to cope with a dangerous biological foe, riven by partisan politics, and led by people who saw little political gain in taking ownership of managing the crisis. A new book on the U.S.

144

144